The history of controlled clinical trials in China. Part 2: from the advent of large-scale multicentre randomised controlled trials through contemporary self-reflection
Restricted accessResearch articleFirst published online August, 2025
The history of controlled clinical trials in China. Part 2: from the advent of large-scale multicentre randomised controlled trials through contemporary self-reflection
WangWLiuLTaoSGongLWuN.
A retrospective drug study of large-scale clinical trials on cardiovascular disease in China. Chin J Cardiol2000;
28: 335–338. [王文,刘力生,陶寿淇,等 (2000). 我国大样本心血管药物临床试验的回顾与展望. 中华心血管病杂志 28(5): 335–338.]
2.
Chinese CEI-AMI Trial Collaborative Group.
Early Intervention with ACE inhibitor captopril in acute myocardial infarction – Chinese multicenter, large-scale, randomized, double-blind, placebo-controlled clinical trial (preliminary analysis of 11345 cases). Chin J Hypertens1994;
2: 67–72. [全国CEI-AMI临床试验协作组(1994). 血管紧张素转换酶抑制剂卡托普利早期治疗急性心肌梗塞随机临床试验全国多中心大规模随机双盲安慰剂对照临床试验11345例阶段小结. 中国高血压杂志 2(2): 67–72.]
3.
Chinese Cardiac Study Collaborative Group.
Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet1995;
345: 686–687.
4.
Chinese CEI-AMI Clinical Research Collaboration, WangWLiuLTaoS.
Clinical trial on the differential effects of captopril in anterior and inferior myocardial infarctions. Chin J Cardiol1995;
23: 165–170. [中国CEI-AMI临床研究协作组,王文,刘力生,等(1995). 卡托普利对前壁与下壁心肌梗塞作用差异的临床试验. 中华心血管病杂志 23(3): 165–170.]
5.
Chinese Cardiac Study-I (CCS-I) Collaboration Group, LiuLWangWTaoS.
Chinese Cardiac Study-I (CCS-I): effects of captopril on the early mortality and complications in 14,962 patients with acute myocardial infarction – a multicenter, large-scale, randomized, double-blind, placebo-controlled clinical trial. Chin J Cardiol1997;
25: 245–249. [中国心脏研究协作组,刘力生,王文,等(1997). 中国心脏研究:卡托普利对急性心肌梗塞患者早期病死率和并发症影响的多中心临床试验——全国大规模随机双盲安慰剂对照临床试验14962例资料总结. 中华心血管病杂志 25: 245–249.]
6.
CAST (Chinese Acute Stroke Trial) Collaborative Group.
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;
349: 1641–1649.
7.
ChenZJiangL.Changing strategies in the management of acute myocardial infarction in modern China. CVD Prevent Control2009;
4: 9–18.
8.
COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet2005;
366: 1607–1621.
9.
COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet2005;
366: 1622–1632.
10.
LiuMCounsellCSandercockP.Report of randomized controlled trials identified in the Chinese literature vs MEDLINE. JAMA1998;
280: 1308–1309.
11.
PATS Collaborating Group.
Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J1995;
108: 710–717.
12.
GuyattGH. Evidence-based medicine. American College of Physicians Journal Club 1991; 114(2): A16.
13.
LiBYanYLvMZhaoGLiZFengS.Clinical epidemiology in China series. Paper 1: evidence-based medicine in China: an oral history study. J Clin Epidemiol2021;
140: 165–171.
14.
LiuM.New methods in clinical stroke research: an introduction to meta-analysis. Int J Cerebrovasc Dis1996;
4: 352–356. [刘鸣 (1996). 脑卒中临床研究的新方法——Meta-分析介绍. 国外医学(脑血管疾病分册) 4(6): 352–356.]
15.
LiYSunXWangL.Evidence-based medicine in China. Value Health2008;
11: S156–S158.
16.
WuTLiYLiuG, Li J, Wang L and Du L.
Chinese clinical trial registry: mission, responsibility and operation. J Evidence-Based Med2011;
4: 165–167.
17.
HsuE.The history of qing hao in the Chinese materia medica. Trans R Soc Trop Med Hyg2006;
100: 505–508.
18.
HuangRWeiYZhouD.Clinical observation on the treatment of malaria using Guangxi Symplocos Chinensis and Artemisia. J Trad Chin Med1959;
4: 33–35. [黄汝绍,韦用宽,周典谟 (1959). 用广西土常山和青蒿两药试治疟疾的临床观察. 中医杂志 4: 33–35.]
19.
TuY.The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med2011;
17: 1217–1220.
TuYLuoZLiGZhangJWuZShiL, et al. Interviews on 523 Project and the Discovery of Artemisinin.
Changsha:
Hunan Education Publishing House, 2015. [屠呦呦,罗泽渊,李国桥,等 (2015). ‘523’任务与青蒿素研发访谈录. 湖南教育出版社.]
22.
SuXMillerL.The discovery of artemisinin and the Nobel Prize in physiology or medicine. Sci China Life Sci2015;
58: 1175–1179.
23.
Qinghaosu Antimalaria Coordinating Research Group.
Antimalaria studies on Qinghaosu. Chin Med J1979;
92: 811–816.
24.
Hubei Academy of Medical Sciences Institute of Parasitic Diseases, Hubei Infectious Disease Hospital of Shashi City and Hubei Health and Epidemic Prevention Station of Shashi City.
Observation of the efficacy of Qinghaosu oil solution in the treatment of malaria. Chin J Med1979;
8: 1–2. [湖北省医学科学院寄生虫病研究所,湖北省沙市市传染病医院,湖北省沙市市卫生防疫站(1979). 青蒿素油剂治疗间日疟效果观察. 中级医刊 8: 1–2.]
25.
LiGQArnoldKGuoXBJianHXFuLC.Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. Lancet1984;
324: 1360–1361.
26.
TianD.The Establishment and Mechanism of Chinese Ethics Review Committees’ System.
Tianjin:
Tianjin Medical University, 2006. [田冬霞 (2006). 中国伦理审查委员会的建构与机制. 天津医科大学.]
WuTLiYLiuGLiJDengSDuL.
The strategies of improving the quality of clinical studies in China. Chin J Evidence-Based Med2010;
10: 1243–1248. [吴泰相,李幼平,刘关键,等 (2010). 中国临床试验注册中心及中国循证医学中心提高我国临床试验质量的策略和措施. 中国循证医学杂志 10(11): 1243–1248.]
29.
WangM.Biomedical journals in China should emphasize informed consent from participants. Chin J Scient Techn Period2000;
11: 293–295. [汪谋岳 (2000). 我国生物医学期刊应重视受试者的知情同意. 中国科技期刊研究 11: 293–295.]
30.
ZhaoHZhangJGuoLYangFZhangMLiY, et al.
The status of registrations, ethical reviews and informed consent forms in RCTs of high impact factor Chinese medical journals. Chin J Evidence-Based Med2018;
18: 735–739. [赵宏杰,张俊华,郭利平,等 (2018). 我国高影响因子中文医学期刊发表随机对照试验注册、伦理、知情同意报告现状及质量评价分析. 中国循证医学杂志 18(7): 735–739.]
31.
Anon.
Reforming research in China. Lancet2007;
369: 880.
32.
Central People’s Government of the People’s Republic of China. Order of the Ministry of Science and Technology of the People’s Republic of China. 2006.11.10. 2006. See www.gov.cn/ziliao/flfg/2006-11/10/content_438430.htm (last checked 16 May 2025). [中华人民共和国中央人民政府 (2006). 中华人民共和国科学技术部令. 2006.11.10.]
33.
Central People’s Government of the People’s Republic of China. The Chinese Academy of Sciences Officially Releases ‘Opinions’ to Further Regulate Research Practices. 2007.2.26. 2007. See www.gov.cn/jrzg/2007-02/26/content_534745.htm (last checked 16 May 2025). [中华人民共和国中央人民政府 (2007). 中科院正式发布《意见》进一步规范科研行为. 2007.2.26.]
34.
LuMJiangM.Study on the supervision mechanism of misconduct in scientific research in China. Sci Technol Progr Policy2011;
28: 100–114. [卢明纯,蒋美仕 (2011). 我国应对科研不端行为的监管机制研究. 科技进步与对策 28(4): 100–104.]
35.
SongTLengHZhongL, Wu T-X and Bian Z-X.
CONSORT in China: past development and future direction. Trials2015;
16: 243.
36.
ZhangDYinPFreemantleN, Jordan R, Zhong N and Cheng KK.
An assessment of the quality of randomised controlled trials conducted in China. Trials2008;
9: 1–8.
37.
LiXTaoKZhouQ, Moher D, Chen H-Y, Wang F-Zet al.
Endorsement of the CONSORT statement by high-impact medical journals in China: a survey of instructions for authors and published papers. PLoS One2012;
7: e30683.
38.
WuTLiYBianZ, Liu G and Moher D.
Randomized trials published in some Chinese journals: how many are randomized?Trials2009;
10: 46.
39.
HeJJinZYuD.Statistical reporting in Chinese biomedical journals. Lancet2009;
373: 2091–2093.
40.
WangJ.Evidence-based medicine in China. Lancet2010;
375: 532–533.
41.
WangJ.Follow international reporting guidelines to raise the quality of articles about clinical research in China. Chin J Digest2010;
30: 1–2. [王吉耀 (2010). 遵循国际标准提高国内临床论文质量. 中华消化杂志 30(1): 1–2.]
42.
HuYHuangYDingJ, et al.
Status of clinical research in China. Lancet2011;
377: 124–125.
43.
WangCLiuQ.A turning point for clinical research in China?Lancet2013;
382: 835–836.
44.
Ministry of Science and Technology of the People’s Republic of China. The National Clinical Medicine Research Centers Officially Launched. 2013.9.4. 2013. See www.most.gov.cn/kjbgz/201309/t20130903_109083.html (last checked 16 May 2025). [中华人民共和国科学技术部 (2013). 国家临床医学研究中心正式启动. 2013.9.4.]
45.
Central People’s Government of the People’s Republic of China. Significant Advances in Medical Technology Innovation and Medical Education Provide Strong Support for the Development of Health and Wellness in China. 2022.8.26. 2022. See www.gov.cn/xinwen/2022-08/26/content_5706894.htm (last checked 16 May 2025). [中华人民共和国中央人民政府 (2022). 医学科技创新与医学教育进步显著 为我国卫生健康事业发展提供有力保障. 2022.8.26.]
46.
JiaYWenJQureshiREhrhardtSCelentanoDD, et al.
Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross-sectional study. BMJ2021;
372: n48.
47.
ChengCWuTShangHLiY-PAltmanDGMoherD, et al.
CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med2017;
167: 112–121.
48.
The BMJ. Acupuncture: How to improve the evidence base. 2022. See https://www.bmj.com/acupuncture (last checked 16 May 2025).
49.
ZhangYJiaoRWittCLaoLLiuJ-PThabaneL, et al.
How to design high quality acupuncture trials – a consensus informed by evidence. BMJ2022;
376; e067476.
50.
International Traditional Medicine Clinical Trial Registry. Terms of References for ITMCTR. Terms of Reference of the ITMCTR Advisory Group. 2022. See http://itmctr.ccebtcm.org.cn/en-US/Home/InformationCode/one (last checked 16 May 2025).
